"10.1371_journal.pone.0076437","plos one","2013-10-03T00:00:00Z","Laura Scolaro; Cristina Parrino; Roberta Coroniti; Laszlo Otvos; Eva Surmacz","Sbarro Institute for Cancer Research and Molecular Medicine, Biotechnology Center, Temple University, Philadelphia, Pennsylvania, United States of America; Department of Biology, Temple University, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: LS CP ES. Performed the experiments: LS CP RC. Analyzed the data: LS CP RC LO ES. Contributed reagents/materials/analysis tools: LO. Wrote the manuscript: CP ES LS.","The compound described in the paper, Allo-aca (leptin receptor antagonist peptide) is covered by the 20120142585 patent application (Leptin antagonist and methods of use) filed on Mar 30, 2010, issued on Jun 07, 2012. The patent is assigned to Temple University. Drs. Surmacz and Otvos Jr. as co-inventors might benefit from future patent licensing. This study was supported by a research grant from Novo Nordisk Diabetes Innovation Award. None of the authors is an employee or consultant for this company, and the company does not own or license patents on compounds described in this study. According the Novo Nordisk award agreement, any and all research results and reports, whether patentable or not, are the sole and exclusive intellectual property of Recipient and/or Institution. The company does not influence or prescreen data submitted for publication. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","10","Laura Scolaro","LS",5,TRUE,3,3,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
